The pivotal role of IL-5 in EGPA pathogenesis is supported by the clinical efficacy of mepolizumab, a humanized monoclonal antibody targeting IL-5, which prevents eosinophil activation and reduces inflammation [117]. This evidence concerns the gene IL5 and eosinophilic granulomatosis with polyangiitis.